b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">\n        <PMID Version="1">31700888</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>08</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Print">2305-5839</ISSN>\n                <JournalIssue CitedMedium="Print">\n                    <Volume>7</Volume>\n                    <Issue>18</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Sep</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Annals of translational medicine</Title>\n                <ISOAbbreviation>Ann Transl Med</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>452</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.21037/atm.2019.08.51</ELocationID>\n            <Abstract>\n                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Four multi-targeted tyrosine kinase inhibitors (TKIs) including apatinib, anlotinib, fruquintinib and lenvatinib are currently available as third-line regimen for advanced non-small cell lung cancer (NSCLC) patients who failed at least two lines of systemic therapy. Limited evidence was provided to demonstrate the general efficacy and safety profile of these drugs as third-line treatment approach for NSCLC.</AbstractText>\n                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Eligible literature was searched from electronic database. Data of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), treatment related adverse event (TRAE), treatment related adverse event grade 3-5 (TRAE3-5), hypertension, proteinuria, hand-foot skin reaction (HFSR), elevated ALT/AST, nausea and vomiting, diarrhea were synthetically extracted. Multiple-treatments comparisons (MTCs) based on a Bayesian consistency model integrated the efficacy and toxicity outcomes. Rank probabilities of each regimen were assessed and clustered by the surface under the cumulative ranking curve.</AbstractText>\n                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Five phase II/III randomized trials involving 915 advanced NSCLC patients were enrolled. MTCs showed that four multi-targeted TKIs shared equivalent efficacy in terms of outcome measures, of which anlotinib stood out in ORR (OR =39.26; 95% CI: 2.36-2,748.06), DCR (OR =8.69; 95% CI: 1.70-50.18) and PFS (HR =0.27; 95% CI: 0.10-0.78) when compared with placebo plus BSC. No significantly differences were observed among these TKIs and placebo with respect to OS, TRAE and TRAE 3-5. Fruquintinib and lenvatinib may relate to high rate of HFSR while anlotinib may relate to hypertension.</AbstractText>\n                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Multi-targeted TKIs (apatinib, anlotinib, fruquintinib and lenvatinib) with acceptable efficacy and safety profile were options for advanced NSCLC in third-line setting.</AbstractText>\n                <CopyrightInformation>2019 Annals of Translational Medicine. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>Zhonghan</ForeName>\n                    <Initials>Z</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhao</LastName>\n                    <ForeName>Yuanyuan</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lu</LastName>\n                    <ForeName>Feiteng</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hou</LastName>\n                    <ForeName>Xue</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ma</LastName>\n                    <ForeName>Yuxiang</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Luo</LastName>\n                    <ForeName>Fan</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zeng</LastName>\n                    <ForeName>Kangmei</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhao</LastName>\n                    <ForeName>Shen</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>Yaxiong</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhou</LastName>\n                    <ForeName>Ting</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yang</LastName>\n                    <ForeName>Yunpeng</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fang</LastName>\n                    <ForeName>Wenfeng</ForeName>\n                    <Initials>W</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Huang</LastName>\n                    <ForeName>Yan</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>Li</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhao</LastName>\n                    <ForeName>Hongyun</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>China</Country>\n            <MedlineTA>Ann Transl Med</MedlineTA>\n            <NlmUniqueID>101617978</NlmUniqueID>\n            <ISSNLinking>2305-5839</ISSNLinking>\n        </MedlineJournalInfo>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Multi-targeted tyrosine kinase inhibitors (multi-targeted TKIs)</Keyword>\n            <Keyword MajorTopicYN="N">anlotinib</Keyword>\n            <Keyword MajorTopicYN="N">apatinib</Keyword>\n            <Keyword MajorTopicYN="N">fruquintinib</Keyword>\n            <Keyword MajorTopicYN="N">lenvatinib</Keyword>\n            <Keyword MajorTopicYN="N">non-small cell lung cancer (NSCLC)</Keyword>\n        </KeywordList>\n        <CoiStatement>Conflicts of Interest: The authors have no conflicts of interest to declare.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>1</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31700888</ArticleId>\n            <ArticleId IdType="doi">10.21037/atm.2019.08.51</ArticleId>\n            <ArticleId IdType="pii">atm-07-18-452</ArticleId>\n            <ArticleId IdType="pmc">PMC6803172</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Biochem J. 2011 Jul 15;437(2):199-213</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21711248</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>JAMA Oncol. 2018 Nov 1;4(11):1569-1575</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30098152</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell. 2011 Mar 4;144(5):646-74</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21376230</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Cancer. 2015 Mar 1;136(5):E359-86</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25220842</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Drugs. 2016 Sep;76(14):1321-36</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27557830</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Oncol. 2012 Jun;19(Suppl 1):S52-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22787411</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet. 2016 Apr 2;387(10026):1354-1356</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26777918</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Cancer. 2018 Mar 6;118(5):654-661</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29438373</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Med Decis Making. 2013 Jul;33(5):641-56</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23804508</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Treat Rev. 2013 May;39(3):252-60</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22703830</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lung Cancer. 2005 Feb;47(2):253-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15639724</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncologist. 2013;18(8):947-53</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23918070</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Invest New Drugs. 2014 Feb;32(1):195-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23728919</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2002 Jan 10;346(2):92-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11784875</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2005 Feb 10;23(5):939-52</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15557593</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2018 Apr;19(4):521-536</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29545095</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Oncol. 2016 Sep;27(suppl 5):v1-v27</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27664245</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2018 Apr 20;36(12):1207-1217</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29528793</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Res Synth Methods. 2012 Jun;3(2):80-97</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26062083</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Pharmacol. 2016 May 15;779:1-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26638998</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lung Cancer. 2015 Mar;87(3):211-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25601484</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Res Synth Methods. 2012 Jun;3(2):111-25</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26062085</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Epidemiol. 2011 Feb;64(2):163-71</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20688472</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Methods Med Res. 2008 Jun;17(3):279-301</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17925316</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Science. 2006 May 26;312(5777):1171-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16728631</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Sci Transl Med. 2016 Feb 10;8(325):325ra17</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26865565</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Future Med Chem. 2012 Sep;4(14):1839-52</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23043480</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Hematol Oncol. 2016 Oct 4;9(1):105</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27716285</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20610543</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Epidemiol. 2016 Aug;76:193-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26939929</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Med. 2016 Mar;22(3):270-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26855149</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>BMJ. 2011 Oct 18;343:d5928</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22008217</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Onco Targets Ther. 2011;4:43-58</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21691577</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell. 2000 Jan 7;100(1):57-70</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">10647931</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2017 Sep 20;8(50):87442-87454</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29152093</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Anticancer Res. 2011 Feb;31(2):649-59</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21378351</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Res Synth Methods. 2012 Jun;3(2):161-76</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26062088</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Pharmacol Ther. 2010 Jan;125(1):105-17</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19874848</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2009 Feb 15;69(4):1263-7; discussion 1267</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19208830</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Rev Cancer. 2010 Feb;10(2):116-29</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20094046</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cardiothorac Surg. 2009 Dec;36(6):1037-44</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19692259</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Natl Compr Canc Netw. 2017 Apr;15(4):504-535</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28404761</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Lung Cancer. 2012 Jan;13(1):39-43</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21890422</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2005 Feb 10;23(5):965-72</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15613696</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2018 Jun 10;36(17):1675-1684</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29570421</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'